Researchers demonstrated a new method of cell lysis using a novel solution to enhance the production of viral vectors.
Adeno-associated virus (AAV) has become a leading platform for gene delivery for the treatment of various diseases due to its excellent safety profile and efficient transduction to various target tissues. However, large-scale production and long-term storage of viral vectors is not efficient, resulting in lower yields, moderate purity, and shorter shelf life compared to recombinant therapeutic proteins. AAV manufacturing includes several upstream, downstream and fill/finish unit operations. Cell lysis is one of the major downstream unit operations, where the outer boundary or cell membrane is broken down or destroyed to release the viral vector from the host cell. During cell lysis and separation of the viral vector from cellular debris, the viral vectors are exposed to high shear stress which aggregates, unfolds and precipitates the virus. In this article, the authors discuss a new cell lysis solution that is efficient and generates little foam, making it easy to use. The new solution also protects the viral vector from shear-induced damage during the manufacturing process, resulting in improved viral vector titer. The solution is ecological and biodegradable.
Submitted: March 18, 2022
Accepted: March 31, 2022
About the authors
Arvind Srivastava*, [email protected], is a technical researcher, research and development; Courtney O’Dell is a senior scientist; Lori Fortin is Senior Research Manager; Jonathan Fura is director, research and development; William Connors is scientist, upstream research-processing; and Nandkumar Deorkar is vice president, research and development; all are at Biopharma Production, Avantor. Michael Hill was previously Principal Investigator at Avantor.
*To whom all correspondence should be addressed.
Flight. 46, No. 5
Pages: 38 to 43
When referencing this article, please cite it as A. Srivastava et al., “A Novel Cell Lysis Method to Improve the Viral Vector Manufacturing Process,” Pharmaceutical technology 46(5) 38–43 (2022).